Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call of ...

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

Potential Additional Cash from Warrant Exercises: Approximately $41 million. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) reported a 39% objective response rate in their phase one trial of ...

On a per-share basis, the Burlingame, California-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...

Honeywell (Nasdaq: HON) has announced that its SwiftDecoder barcode-decoding software will be integrated into Corvus Robotics ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Corvus Pharmaceuticals Inc. (CRVS) on Tuesday reported a loss of $12.1 million in its fourth quarter. The Burlingame, California-based ...